Augmented cytotoxicity of estramustine and etoposide combination in hormone refractory prostate cancer cell lines and association with TGF modulation

被引：0
作者：
LN Türkeri
O Ayaz
M Özyürek
A Akdas
机构：
[1] ‘Ergun Özalp’ Research Laboratory,Department of Urology
[2] Marmara University School of Medicine,undefined
来源：
Prostate Cancer and Prostatic Diseases | 1999年 / 2卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：S33 / S33
相关论文
共 50 条
[41]   Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer [J].
Matsumoto, Akihiro ;
Inoue, Atsushi ;
Yokoi, Satoshi ;
Nozumi, Kazuyoshi ;
Miyazaki, Kanetaka ;
Hosoki, Shigeru ;
Nagata, Maki ;
Yamaguchi, Kunio .
INTERNATIONAL JOURNAL OF UROLOGY, 2009, 16 (08) :687-691
[42]   Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer [J].
Kobayashi, Mizuki ;
Kuramoto, Hiroshi ;
Ota, Junichiro ;
Fujimoto, Naohiro .
INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (07) :1019-1021
[43]   TREATMENT OF ADVANCED HORMONE-REFRACTORY PROSTATE CARCINOMA WITH A COMBINATION OF ETOPOSIDE, PIRARUBICIN AND CISPLATIN [J].
NAITO, S ;
UEDA, T ;
KOTOH, S ;
KUMAZAWA, J ;
ITOH, K ;
SAGIYAMA, K ;
OMOTO, T ;
ANDOH, S ;
HASEGAWA, Y ;
FUJISAWA, Y .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (03) :225-229
[44]   Enhanced cytotoxicity and apoptosis by thymoquinone in combination with zoledronic acid in hormone- and drug-resistant prostate cancer cell lines [J].
Dirican, Ahmet ;
Erten, Cigdem ;
Atmaca, Harika ;
Bozkurt, Emir ;
Kucukzeybek, Yuksel ;
Varol, Umut ;
Tarhan, Mustafa Oktay ;
Karaca, Burcak ;
Uslu, Ruchan .
JOURNAL OF BUON, 2014, 19 (04) :1055-1061
[45]   Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer [J].
Segawa T. ;
Kamoto T. ;
Kinoshita H. ;
Kunishima Y. ;
Yoshimura K. ;
Ito A. ;
Takahashi T. ;
Higashi S. ;
Nakamura E. ;
Nishiyama H. ;
Ito N. ;
Yamamoto S. ;
Habuchi T. ;
Ogawa O. .
International Journal of Clinical Oncology, 2005, 10 (5) :333-337
[46]   A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer [J].
Berry, William ;
Friedland, David ;
Fleagle, John ;
Jackson, Dori ;
Ilegbodu, Des ;
Boehm, Kristi A. ;
Asmar, Lina .
CLINICAL GENITOURINARY CANCER, 2006, 5 (02) :131-137
[47]   EFFICACY AND SAFETY OF THE ASSOCIATION OF PACLITAXEL AND ESTRAMUSTINE WITH ZOLENDRONIC ACID, IN METASTATIC HORMONE-REFRACTORY PROSTATE CARCINOMA [J].
Chiesa, M. Dalla ;
Negri, F. ;
Bergonzi, C. ;
Musolino, A. ;
Perrone, A. ;
Potenzoni, D. ;
Cantoni, C. ;
Di Giovanni, M. ;
Donati, G. V. ;
Passalacqua, R. .
ANNALS OF ONCOLOGY, 2004, 15 :97-97
[48]   A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer [J].
Lin, Amy M. ;
Rini, Brian I. ;
Derynck, Mika K. ;
Weinberg, Vivian ;
Park, Margaret ;
Ryan, Charles J. ;
Rosenberg, Jonathan E. ;
Bubley, Glenn ;
Small, Eric J. .
CLINICAL GENITOURINARY CANCER, 2007, 5 (05) :323-328
[49]   Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: A single-center experience [J].
Boehmer, A ;
Anastasiadis, AG ;
Feyerabend, S ;
Nagele, U ;
Kuczyk, M ;
Schilling, D ;
Corvin, S ;
Merseburger, AS ;
Stenzl, A .
ANTICANCER RESEARCH, 2005, 25 (6C) :4481-4486
[50]   Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients [J].
Nakagami, Yoshihiro ;
Ohori, Makoto ;
Sakamoto, Noboru ;
Koga, Shoji ;
Hamada, Riu ;
Hatano, Tadashi ;
Tachibana, Masaaki .
INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 (07) :629-634
12345